Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
05:47am, Sunday, 26'th Jul 2026
These two companies are pharmaceutical giants. Both seem somewhat overvalued at recent levels.
Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75?
06:46pm, Saturday, 25'th Jul 2026
Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whet
Why Wall Street Can't Get Enough of This Dividend King
10:15am, Saturday, 25'th Jul 2026
AbbVie inherited its Dividend King status, but has proven to be a good dividend steward. The company's 2.7% yield is well-above the pharmaceutical average.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:01am, Friday, 24'th Jul 2026
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie: A Dividend Fortress At An Appealing Price Tag
10:46am, Friday, 24'th Jul 2026
AbbVie earns a buy rating, supported by accelerating top and bottom-line growth and a compelling valuation at 18x forward P/E. ABBV offers a 2.7% forward dividend yield, outperforming peers by 68%, an
Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC's ‘Final Trades'
07:53am, Friday, 24'th Jul 2026
On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE:ABBV).
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 st
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC?
03:39pm, Thursday, 23'rd Jul 2026
One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.
I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation
11:15am, Thursday, 23'rd Jul 2026
When quality goes on sale, it's time to back up the truck.
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
08:15am, Thursday, 23'rd Jul 2026
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?
07:49am, Thursday, 23'rd Jul 2026
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
4,373 Shares in AbbVie Inc. $ABBV Acquired by Ascension Capital Advisors Inc.
04:21am, Thursday, 23'rd Jul 2026
Ascension Capital Advisors Inc. bought a new position in AbbVie Inc. (NYSE: ABBV) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,373
AR Asset Management Inc. Acquires 2,266 Shares of AbbVie Inc. $ABBV
03:47am, Thursday, 23'rd Jul 2026
AR Asset Management Inc. raised its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 5.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 45,226 shares of t
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?
01:40pm, Wednesday, 22'nd Jul 2026
ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
06:45am, Wednesday, 22'nd Jul 2026
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
